Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: J Immunother. 2012 Oct;35(8):615–620. doi: 10.1097/CJI.0b013e31826e8f5f

Table III.

Infused TIL Characteristics

Patient # Days1 Expansion2 # TIL Infused Viability %CD4 / %CD8
2 52 1567 4.7×1010 93% 42 / 56
4 45 1133 3.4×1010 93% 37 / 57
5 192 1433 4.3×1010 83% 1 / 94
7 101 1040 5.2×1010 84% 88 / 6
8 45 1340 6.3×1010 82% 7 / 88
9 39 1480 7.4×1010 80% 1 / 96
12 110 400 2.0×1010 85% 66 / 33
13 47 1217 7.3×1010 79% 4 / 82
15 38 1100 6.6×1010 91% 5 / 89
16 45 1100 11.0×1010 95% 9 / 80
17 53 630 3.8×1010 82% 68 / 30
18 40 1300 7.8×1010 84% 10 / 90
19 53 550 3.3×1010 83% 66 / 23
Mean 66 1099 5.6×1010 85% 31 / 63
1

Days from surgical resection to TIL infusion

2

Fold-expansion of TIL during Rapid Expansion